Product Details
Product Name:
Enloplatin |
CAS No.:
111523-41-2 |
Purity:
99.73% |
Supply Ability:
10g |
Release date:
2024/11/19 |
Product Introduction
Bioactivity
Name | Enloplatin |
Description | Enloplatin is a carboplatin analog that has a partial role in advanced ovarian cancer. |
In vivo | Enloplatin (i.v. infusion; over 1.5 h; every 21 days), one patient had a partial response (6%; 95% CI 0-26%) lasting 2.8 months. The median survival was 9.4 months (95%; CI 5.1-19.7%). Neutropenia was the dose-limiting toxicity. Nephrotoxicity was manageable. Enloplatin is the major form of the free drug in plasma. However, 13.5 h after initiation of treatment, 85% of the drug in plasma is protein bound. Elimination of the drug is mainly renal.[1] |
Storage | keep away from direct sunlight | Shipping with blue ice. |
Solubility Information | DMSO : 55 mg/mL (114.25 mM)
|
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:320-67-2
$33.00 / 50mg
-
CAS:14255-87-9
$46.00 / 10mg
-
CAS:388592-44-7
$33.00 / 5mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |